Schizophrenia (SCZ) genomics has achieved unprecedented advances. A decade ago, there was perhaps one solid finding, and there are now 130+ loci that meet consensus criteria for significance and replication. The Swedish SCZ Study (S3) and its investigators were centrally important to these advances. Genetic analyses of S3 samples have been major parts of multiple high profile papers. We cooperate well with other groups, and are leaders in the PGC. There is more to do. Thus, this is a competitive renewal for the S3 project. The S3 is arguably the largest and best-characterized SCZ sample anywhere: we propose to make it larger and more informative. In each prior R01, we accomplished far more than we proposed. We now propose aims designed to maximize the informativeness of S3 by doubling its size, adding cognitive phenotypes, and innovative analyses. Critically, this work is multi-funded and maximizes contributions from others and minimizes NIH budgetary requests.
Specific Aims (1) Augment S3 dataset by doubling the sample size, add cognitive phenotypes, conduct comprehensive genomic characterization, impute to a Sweden-specific reference panel, and add new Swedish register linkages. Output: a large and comprehensive dataset ready for analysis. (2) Analysis: increase knowledge of the genetic basis of SCZ. Integrate data from Aim 1 with all other world samples to discover compellingly associated loci. Add multi-omic integration: combine, annotate, and rigorously evaluate results with all available epigenomic and gene expression data (e.g., CommonMind, psychENCODE). Output: SCZ associations across the allelic spectrum, specific hypotheses about the immediate biological impact of genetic variation implicated in SCZ. Successful completion of this work - capitalizing on cutting-edge technologies and a highly productive decade- long collaboration - is highly likely to advance knowledge of SCZ by identifying more loci, providing specific biological hypotheses, and understanding of GxE action and interaction. This study is preclinical. Although not proposed here due to complexity and expense, we will immediate prioritize any potential therapeutic target via collaborations (e.g., with Dr Sullivan's UNC colleague and antipsychotic expert Dr Bryan Roth). The work proposed is highly efficient / cost-effective due to our multi-funding model. We have minimized costs (while maximizing the science we can achieve) via multiple strategic partnerships. We use consultancies to bring well-funded investigators into S3. We routinely use multiple technologies to enhance collaboration.

Public Health Relevance

The Swedish SCZ Study (S3) is arguably the largest and best-characterized SCZ sample in the world: we propose to make it larger and more informative. In each prior R01, we accomplished far more than we proposed. We now propose aims designed to maximize the informativeness of S3 by doubling its size, adding cognitive phenotypes, and innovative analyses. This work is highly likely to increase knowledge of the genetic basis of SCZ and its clinical and population relevance.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Addington, Anjene M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Schools of Medicine
New York
United States
Zip Code
Marshall, Christian R (see original citation for additional authors) (2017) Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27-35
Visscher, Peter M; Wray, Naomi R; Zhang, Qian et al. (2017) 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet 101:5-22
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Nguyen, Hoang T; Bryois, Julien; Kim, April et al. (2017) Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders. Genome Med 9:114
Leonenko, Ganna; Richards, Alexander L; Walters, James T et al. (2017) Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 174:724-731
Direk, Nese; Williams, Stephanie; Smith, Jennifer A et al. (2017) An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biol Psychiatry 82:322-329
Genovese, Giulio; Fromer, Menachem; Stahl, Eli A et al. (2016) Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat Neurosci 19:1433-1441
Ruderfer, Douglas M; Charney, Alexander W; Readhead, Ben et al. (2016) Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 3:350-7
Lek, Monkol; Karczewski, Konrad J; Minikel, Eric V et al. (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285-91
Franke, Barbara; Stein, Jason L; Ripke, Stephan et al. (2016) Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nat Neurosci 19:420-431

Showing the most recent 10 out of 29 publications